Enhancing Calm in Arab Elderly With Dementia (NCT06216275) | Clinical Trial Compass
UnknownNot Applicable
Enhancing Calm in Arab Elderly With Dementia
Egypt80 participantsStarted 2024-01-05
Plain-language summary
The goal of this clinical trial is to evaluate the effectiveness of integrating Snoezelen methods with aromatherapy and personal items in reducing agitation in Arab elderly individuals with dementia. The main questions it aims to answer are:
Does the combination of Snoezelen methods, aromatherapy, and the use of personal items significantly reduce agitation in elderly Arab patients with dementia compared to standard care practices? How do patients and caregivers perceive the impact of this integrated approach on the overall well-being and quality of life of the patients?
Participants in this study will:
Engage in sessions utilizing Snoezelen methods, a multi-sensory environment designed to deliver stimuli to various senses.
Receive aromatherapy treatments with selected scents known for their calming properties.
Be provided with personal items that are familiar and meaningful to them, to create a sense of comfort and security.
Who can participate
Age range
60 Years – 90 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
For the study \"Enhancing Calm in Arab Elderly with Dementia: Integrating Snoezelen Methods with Aromatherapy and Personal Items to Reduce Agitation\", here are the suggested Inclusion and Exclusion Criteria:
Inclusion Criteria:
* Age: Participants must be 65 years to 90 years
* Diagnosis: Clinical diagnosis of dementia required.
* Ethnicity: Must be of Arab descent.
* Agitation Levels: Must show agitation signs based on a standardized scale.
* Cognitive Function: Adequate cognitive function for study participation, verified by standard assessment.
Exclusion Criteria:
* Severe Medical Conditions: Individuals with severe medical conditions that could affect study participation or health.
* Advanced Dementia: Patients with very advanced dementia stages, unable to engage in study activities.
* Allergies: Known allergies to aromatherapy products used in the study.
* Recent Medication Changes: Significant changes in dementia medication regimen before the study.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.